• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Hoitt Jason claimed ownership of 1,802 shares (SEC Form 3)

    6/23/25 4:16:10 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $STOK alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Hoitt Jason

    (Last) (First) (Middle)
    C/O STOKE THERAPEUTICS, INC.
    45 WIGGINS AVENUE

    (Street)
    BEDFORD MA 01730

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    06/18/2025
    3. Issuer Name and Ticker or Trading Symbol
    Stoke Therapeutics, Inc. [ STOK ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Patient Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 1,802 D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Employee Stock Option (Right to Buy) (1) 04/14/2034 Common Stock 265,000 $12.21 D
    Employee Stock Option (Right to Buy) (2) 08/14/2034 Common Stock 65,000 $14.25 D
    Employee Stock Option (Right to Buy) (3) 03/19/2035 Common Stock 60,000 $8.33 D
    Employee Stock Option (Right to Buy) (4) 06/15/2035 Common Stock 90,000 $11.7 D
    Restricted Stock Units (5) 03/15/2029 Common Stock 40,000 (6) D
    Explanation of Responses:
    1. The option vested or vests as to 1/4 of the total award on April 8, 2025, with another 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
    2. The option shall vest as to 1/4 of the total award on August 15, 2025, with another 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
    3. The option vested or vests as to 1/48 of the total award on April 15, 2025, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
    4. The option vested or vests as to 1/48 of the total award on July 16, 2025, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
    5. The award shall vest as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the issuer through each vesting date.
    6. Each restricted stock unit represents a contingent right to receive one share of the issuer's Common Stock upon settlement.
    /s/ Jonathan Allan, Attorney-in-Fact 06/23/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $STOK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STOK

    DatePrice TargetRatingAnalyst
    12/20/2024$24.00Buy
    Chardan Capital Markets
    10/14/2024$18.00Outperform
    Leerink Partners
    3/26/2024Market Perform → Outperform
    TD Cowen
    11/20/2023Neutral
    JP Morgan
    7/25/2023Outperform → Market Perform
    TD Cowen
    5/1/2023$9.00 → $12.00Underperform → Neutral
    BofA Securities
    4/26/2023$24.00Buy
    Canaccord Genuity
    1/6/2023$22.00 → $9.00Buy → Underperform
    BofA Securities
    More analyst ratings

    $STOK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Hoitt Jason claimed ownership of 1,802 shares (SEC Form 3)

      3 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

      6/23/25 4:16:10 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Skorpios Trust sold $30,600,000 worth of shares (3,000,000 units at $10.20) (SEC Form 4)

      4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

      6/6/25 4:20:31 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Smith Julie

      4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

      6/4/25 8:38:05 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care